LA JOLLA PHARMACEUTICAL CO Form 8-K May 12, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)

0-24274

(Commission

File Number)

Delaware

(State or other jurisdiction of incorporation)

4365 Executive Drive, Suite 300, San Diego, California

(Address of principal executive offices)

Registrant s telephone number, including area code:

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

33-0361285

(I.R.S. Employer Identification No.)

92121

(Zip Code)

(858) 452-6600

May 11, 2011

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

Top of the FormItem 8.01Other Events.

On May 11, 2011, La Jolla Pharmaceutical Company (the Company) reported that on that date it had converted approximately 14 shares of Series C-1¹ Convertible Preferred Stock into 2,350,000 shares of common stock. Following these conversions, the Company had a total of 6,364,327 shares of common stock issued and outstanding.

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

Top of the Form

May 11, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

La Jolla Pharmaceutical Company

By: /s/ Gail A. Sloan

Name: Gail A. Sloan Title: Chief Financial Officer and Secretary